PLPL Plandai Biotechnology Inc (PK)

Plandai Biotechnology, Inc. Announces Phytofare(TM) Catechin Complex Shows Over Two Times the Level of Catechins Compared to Generic Extract

Test Results Help Validate Plandai's Extraction Process

SEATTLE, WA--(Marketwired - Jun 24, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has received test results from North-West University that indicate that Plandaí's Phytofare™ Catechin Complex, which is derived from green tea phyto-nutrients, contains 2.2 times the amount of catechins by weight when compared to generic green tea extracts.

The testing, conducted by Prof. Anne Grobler, the Director of Preclinical Platform, Department of Pharmacology with North-West University in Potchefstroom, South Africa, included a full chemical profile. The results showed that Phytofare™ Catechin Complex contained between 80-88% catechins by weight, compared to around 40% in the generic samples. As with the generic extracts, the dominant catechin in Phytofare™ Catechin Complex is EGCG (epigallocatechin-3-gallate), which has been the subject of numerous investigative studies testing its potential use as a therapeutic for a broad range of applications including HIV, cancers, malaria, neuro-degradation diseases, weight loss, and anti-aging.

Vice President of Sales Callum Baylis-Duffield commented, "While the increased level of catechins should not be confused with increased bioavailability, it does show that our live-plant extraction process is more efficient. The testing conducted by North-West University affirms our belief that the extraction methodology involved in producing Phytofare yields a superior finished product, which we believe will demonstrate superior clinical results. Further refinements to the system, as we draw closer to commercial production, should help us push that efficiency even higher towards our goal of 95% catechin purity by weight."

Mr. Baylis-Duffield added, "Since we use living plant material rather than dried leaf, the anti-oxidants are still quite active throughout the process. The test data showed that a lot was happening to the overall structure of the molecules during our process in addition to merely increasing catechin yields, which we are further analyzing to determine the effect on solubility, absorption and bioavailability."

Plandaí's first product to market will be Phytofare™ Catechin Complex, which includes the entire Catechin profile derived from live green tea that is grown and processed on the Company's 30,000 sq. ft. factory located on its Senteeko estate in South Africa. The company's Phytofare™ Citrus Complex, based on citrus bioflavonoids and limonoids, will start undergoing clinical testing later this year in anticipation of a 2015 release.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Contact: Andrew Beyer Phone: 619-202-7456 Email: investor@Plandaíbiotech.com